Global Phenylketonuria (PKU) Treatment Market, By Type (Hyperphenylalaninemia, Mild PKU, Moderate or Variant and Classic PKU), Drugs Type (Kuvan, Sapropterin, Palynziq, Pagvaliase, Biopten), Therapy Type (Gene Therapy, Dietary Therapy), Route of Administration (Oral, Intravenous, Subcutaneous, Others), End-User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Phenylketonuria (PKU) Treatment Market
Phenylketonuria (PKU) treatment market size is projected to grow at a compound annual growth rate of 10.95% over the forecast period of 2022 to 2029. Data Bridge Market Research report on phenylketonuria (PKU) treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Phenylketonuria (PKU) is basically a rare inherited genetic disorder which increases the levels of phenylalanine (an amino acid) in the blood. Phenylalanine is an amino acid which is comprised of proteins obtained from food and diet. Phenylalanine hydroxylase enzyme converts phenylalanine in to tyrosine amino acid in human body. The excess of phenylalanine in the blood can cause psychiatric disorders, seizures and many other untreated disorders.
The rise in the research in the field of genomics and bioinformatics and rise in the awareness amongst the people across the globe is expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the increase in the research in the field of genomics and bioinformatics and increase in the development and commercialization of new drugs will further carve the way for the growth of the market. The rise in the technological advancements and modernization in the production techniques and rise in the demand from emerging economies are also expected to boost the overall growth of the market within the above mentioned forecast period. However, the rise in the overall high cost of treatment is projected to restraint the market growth rate. On the other hand, the stringent government regulations also hampers the overall growth of the market.
In addition, the rise in the research and development activities in the market coupled with surge in the advancements in the health care industry are likely to create various new opportunities that will impact this phenylketonuria (PKU) treatment market growth in the forecast period of 2022 to 2029.The factors such as unfavorable reimbursement and rise in the lack of awareness among the patient and physician about phenylketonuria are estimated to challenge the market’s growth.
This phenylketonuria (PKU) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the phenylketonuria (PKU) treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Phenylketonuria (PKU) Treatment Market Scope and Market Size
Phenylketonuria (PKU) treatment market is segmented on the basis of type, drugs type, therapy type, route of administration and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the phenylketonuria (PKU) treatment market is segmented into hyperphenylalaninemia, mild PKU and moderate or variant and classic PKU.
- Based on drugs type, the phenylketonuria (PKU) treatment market is segmented into kuvan, sapropterin, palynziq, pagvaliase and biopten.
- Based on therapy type, the phenylketonuria (PKU) treatment market is segmented into gene therapy and dietary therapy.
- Based on route of administration, the phenylketonuria (PKU) treatment market is segmented into oral, intravenous, subcutaneous and others.
- The phenylketonuria (PKU) treatment market is also segmented on the basis of end-user into hospitals, homecare, specialty clinics and others.
Phenylketonuria (PKU) Treatment Market Country Level Analysis
Phenylketonuria (PKU) treatment market is analyzed and market size information is provided by type, drugs type, therapy type, route of administration and end-user as referenced above.
The countries covered in the phenylketonuria (PKU) treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the phenylketonuria (PKU) treatment market due to the rise in the favorable regulations, rising government initiatives for the treatment of PKU and continuous research and development and commercialization of novel drugs in this region. Europe region, on the other hand is projected to expand at a significant growth rate because of the rise in the awareness amongst the people and increase in the research in the field of genomics and bioinformatics in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Phenylketonuria (PKU) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Phenylketonuria (PKU) Treatment Market Share Analysis
Phenylketonuria (PKU) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to phenylketonuria (PKU) treatment market.
Some of the major players operating in the phenylketonuria (PKU) treatment market report are DAIICHI SANKYO COMPANY, Ajinomoto Cambrooke, Inc., Applied Biomedical, LLC, MTW Endoskopie Manufaktur, American Gene Technologies., Ultragenyx Pharmaceutical, Nutricia, Reckitt Benckiser Group plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Solvay, Abbott, Promin, SOM BIOTECH, Synthetic Biologics, Inc., Nestlé India Ltd., Codexis, BioMarin and Erytech Pharma among others.
SKU-